25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AQS (Aequus Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aequus Pharmaceuticals Inc together

I guess you are interested in Aequus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aequus Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aequus Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Aequus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aequus Pharmaceuticals Inc

I send you an email if I find something interesting about Aequus Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Aequus Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aequus Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$-0.05
Expected worth in 1 year
C$-0.07
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
C$-0.02
Return On Investment
-326.1%

For what price can you sell your share?

Current Price per Share
C$0.01
Expected price per share
C$0.005 - C$0.005
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aequus Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
C$0.01
Intrinsic Value Per Share
C$-0.08 - C$0.05
Total Value Per Share
C$-0.14 - C$-0.01

2.2. Growth of Aequus Pharmaceuticals Inc (5 min.)




Is Aequus Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.2m-$2.8m-$1.7m-38.5%

How much money is Aequus Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$395.9k-$528.2k$132.2k33.4%
Net Profit Margin-305.1%-2,348.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Aequus Pharmaceuticals Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aequus Pharmaceuticals Inc?

Welcome investor! Aequus Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Aequus Pharmaceuticals Inc.

First you should know what it really means to hold a share of Aequus Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Aequus Pharmaceuticals Inc is C$0.005. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aequus Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aequus Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$-0.05. Based on the TTM, the Book Value Change Per Share is C$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is C$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aequus Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.00-71.3%0.00-59.7%0.00-79.6%0.00-71.1%0.00-61.3%0.00-81.2%
Usd Book Value Change Per Share0.00-72.4%0.00-59.8%0.00-78.2%0.00-73.7%0.00-32.4%0.00-25.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-72.4%0.00-59.8%0.00-78.2%0.00-73.7%0.00-32.4%0.00-25.4%
Usd Price Per Share0.00-0.01-0.02-0.02-0.05-0.13-
Price to Earnings Ratio-0.26--0.98--1.25--1.48--5.83--8.11-
Price-to-Total Gains Ratio-1.01--3.84--5.11--5.76--22.22--31.06-
Price to Book Ratio-0.09--0.32--1.06-3.46-6.97-18.38-
Price-to-Total Gains Ratio-1.01--3.84--5.11--5.76--22.22--31.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.003665
Number of shares272851
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (272851 shares)-815.16-442.66
Gains per Year (272851 shares)-3,260.63-1,770.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3261-32710-1771-1781
20-6521-65320-3541-3552
30-9782-97930-5312-5323
40-13043-130540-7083-7094
50-16303-163150-8853-8865
60-19564-195760-10624-10636
70-22824-228370-12395-12407
80-26085-260980-14165-14178
90-29346-293590-15936-15949
100-32606-326200-17706-17720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.046.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%8.032.00.020.0%10.034.02.021.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%8.032.00.020.0%10.034.02.021.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aequus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.005-0.004-18%-0.005+8%-0.005+2%-0.002-55%-0.002-65%
Book Value Per Share---0.054-0.048-11%-0.029-45%-0.028-48%-0.013-75%-0.001-98%
Current Ratio--0.0440.050-13%0.087-50%0.195-78%1.900-98%2.355-98%
Debt To Asset Ratio--24.37312.062+102%4.675+421%6.171+295%4.034+504%2.258+979%
Debt To Equity Ratio----0%-0%1.503-100%1.758-100%1.469-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---6751484.845-5186217.304-23%-1133615.148-83%-931385.115-86%5867892.255-215%22530387.178-130%
Eps---0.005-0.004-16%-0.005+12%-0.0050%-0.004-14%-0.006+14%
Ev To Sales Ratio---7.450-6.840-8%-6.267-16%-3.479-53%0.669-1214%16.957-144%
Free Cash Flow Per Share--0.000-0.002+969%-0.005+2110%-0.004+1613%-0.003+1321%-0.004+1966%
Free Cash Flow To Equity Per Share--0.0000.000+459%0.000-122%-0.001+1588%0.000-203%0.000-719%
Gross Profit Margin--1.0001.0000%1.344-26%1.287-22%1.714-42%1.585-37%
Intrinsic Value_10Y_max--0.045----------
Intrinsic Value_10Y_min---0.082----------
Intrinsic Value_1Y_max---0.012----------
Intrinsic Value_1Y_min---0.016----------
Intrinsic Value_3Y_max---0.023----------
Intrinsic Value_3Y_min---0.042----------
Intrinsic Value_5Y_max---0.019----------
Intrinsic Value_5Y_min---0.061----------
Market Cap663170.0000%663172.1551906619.946-65%3647446.853-82%3785607.718-82%8803598.505-92%23965314.253-97%
Net Profit Margin---2.848-3.051+7%-23.487+725%-10.046+253%-6.376+124%-4.798+68%
Operating Margin----0%-22.3170%-8.4770%-5.3490%-4.2690%
Operating Ratio--1.7843.832-53%23.317-92%10.425-83%6.919-74%5.464-67%
Pb Ratio-0.0930%-0.093-0.319+242%-1.058+1035%3.455-103%6.968-101%18.380-101%
Pe Ratio-0.2570%-0.257-0.977+280%-1.249+386%-1.478+475%-5.832+2169%-8.107+3055%
Price Per Share0.0050%0.0050.014-65%0.028-82%0.029-82%0.066-92%0.181-97%
Price To Free Cash Flow Ratio5.2290%5.229-0.385+107%-1.533+129%-1.573+130%2.314+126%-3.058+158%
Price To Total Gains Ratio-1.0120%-1.012-3.844+280%-5.110+405%-5.758+469%-22.224+2097%-31.063+2970%
Quick Ratio--0.0120.011+2%0.059-80%0.149-92%1.753-99%2.176-99%
Return On Assets---2.121-0.946-55%-0.686-68%-0.699-67%-0.467-78%-0.438-79%
Return On Equity----0%-0%-0.4730%-0.4130%-0.5890%
Total Gains Per Share---0.005-0.004-18%-0.005+8%-0.005+2%-0.002-55%-0.002-65%
Usd Book Value---5211951.787-4654450.129-11%-2862896.425-45%-2733478.983-48%-1309417.530-75%-100112.389-98%
Usd Book Value Change Per Share---0.004-0.003-18%-0.004+8%-0.004+2%-0.002-55%-0.001-65%
Usd Book Value Per Share---0.039-0.035-11%-0.022-45%-0.021-48%-0.010-75%-0.001-98%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---4948838.391-3801497.284-23%-830939.903-83%-682705.289-86%4301165.023-215%16514773.801-130%
Usd Eps---0.004-0.003-16%-0.004+12%-0.0040%-0.003-14%-0.004+14%
Usd Free Cash Flow--23240.498-202042.471+969%-467048.176+2110%-351535.439+1613%-283827.532+1321%-433595.815+1966%
Usd Free Cash Flow Per Share--0.000-0.002+969%-0.004+2110%-0.003+1613%-0.002+1321%-0.003+1966%
Usd Free Cash Flow To Equity Per Share--0.0000.000+459%0.000-122%-0.001+1588%0.000-203%0.000-719%
Usd Market Cap486103.6100%486105.1901397552.420-65%2673578.543-82%2774850.457-82%6453037.704-92%17566575.347-97%
Usd Price Per Share0.0040%0.0040.011-65%0.020-82%0.021-82%0.049-92%0.132-97%
Usd Profit---472859.033-395943.877-16%-528215.560+12%-493592.671+4%-419520.346-11%-556016.875+18%
Usd Revenue--166057.485138945.098+20%39435.400+321%130911.968+27%262901.848-37%231565.365-28%
Usd Total Gains Per Share---0.004-0.003-18%-0.004+8%-0.004+2%-0.002-55%-0.001-65%
 EOD+0 -2MRQTTM+11 -22YOY+15 -193Y+17 -185Y+9 -2610Y+12 -23

3.3 Fundamental Score

Let's check the fundamental score of Aequus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.257
Price to Book Ratio (EOD)Between0-1-0.093
Net Profit Margin (MRQ)Greater than0-2.848
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.012
Current Ratio (MRQ)Greater than10.044
Debt to Asset Ratio (MRQ)Less than124.373
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.121
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Aequus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.711
Ma 20Greater thanMa 500.005
Ma 50Greater thanMa 1000.005
Ma 100Greater thanMa 2000.006
OpenGreater thanClose0.005
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Aequus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2025-06-27 00:56:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aequus Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -284.8%Β means thatΒ $-2.85 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aequus Pharmaceuticals Inc:

  • The MRQ is -284.8%. The company is making a huge loss. -2
  • The TTM is -305.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-284.8%TTM-305.1%+20.4%
TTM-305.1%YOY-2,348.7%+2,043.6%
TTM-305.1%5Y-637.6%+332.4%
5Y-637.6%10Y-479.8%-157.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aequus Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • -212.1% Return on Assets means thatΒ Aequus Pharmaceuticals Inc generatedΒ $-2.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aequus Pharmaceuticals Inc:

  • The MRQ is -212.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -94.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-212.1%TTM-94.6%-117.4%
TTM-94.6%YOY-68.6%-26.1%
TTM-94.6%5Y-46.7%-48.0%
5Y-46.7%10Y-43.8%-2.8%
4.3.1.3. Return on Equity

Shows how efficient Aequus Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Aequus Pharmaceuticals Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-41.3%+41.3%
5Y-41.3%10Y-58.9%+17.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aequus Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aequus Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Aequus Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,231.7%+2,231.7%
TTM-5Y-534.9%+534.9%
5Y-534.9%10Y-426.9%-108.0%
4.3.2.2. Operating Ratio

Measures how efficient Aequus Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.78 means that the operating costs are $1.78 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 1.784. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.832. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.784TTM3.832-2.047
TTM3.832YOY23.317-19.485
TTM3.8325Y6.919-3.088
5Y6.91910Y5.464+1.455
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aequus Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aequus Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.04Β means the company has $0.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 0.044. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.050. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.044TTM0.050-0.007
TTM0.050YOY0.087-0.037
TTM0.0505Y1.900-1.850
5Y1.90010Y2.355-0.455
4.4.3.2. Quick Ratio

Measures if Aequus Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.01Β means the company can pay off $0.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 0.012. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.011. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.012TTM0.011+0.000
TTM0.011YOY0.059-0.048
TTM0.0115Y1.753-1.742
5Y1.75310Y2.176-0.423
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aequus Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aequus Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aequus Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 24.37Β means that Aequus Pharmaceuticals Inc assets areΒ financed with 2,437.3% credit (debt) and the remaining percentage (100% - 2,437.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 24.373. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 12.062. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ24.373TTM12.062+12.310
TTM12.062YOY4.675+7.387
TTM12.0625Y4.034+8.028
5Y4.03410Y2.258+1.776
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aequus Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aequus Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.758-1.758
5Y1.75810Y1.469+0.289
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Aequus Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aequus Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.26 means the investor is paying $-0.26Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aequus Pharmaceuticals Inc:

  • The EOD is -0.257. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.257. Based on the earnings, the company is expensive. -2
  • The TTM is -0.977. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.257MRQ-0.2570.000
MRQ-0.257TTM-0.977+0.720
TTM-0.977YOY-1.249+0.271
TTM-0.9775Y-5.832+4.854
5Y-5.83210Y-8.107+2.276
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aequus Pharmaceuticals Inc:

  • The EOD is 5.229. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.229. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -0.385. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.229MRQ5.2290.000
MRQ5.229TTM-0.385+5.614
TTM-0.385YOY-1.533+1.148
TTM-0.3855Y2.314-2.699
5Y2.31410Y-3.058+5.372
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aequus Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -0.09 means the investor is paying $-0.09Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aequus Pharmaceuticals Inc:

  • The EOD is -0.093. Based on the equity, the company is expensive. -2
  • The MRQ is -0.093. Based on the equity, the company is expensive. -2
  • The TTM is -0.319. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.093MRQ-0.0930.000
MRQ-0.093TTM-0.319+0.225
TTM-0.319YOY-1.058+0.740
TTM-0.3195Y6.968-7.286
5Y6.96810Y18.380-11.412
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets304
Total Liabilities7,415
Total Stockholder Equity-7,110
 As reported
Total Liabilities 7,415
Total Stockholder Equity+ -7,110
Total Assets = 304

Assets

Total Assets304
Total Current Assets304
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 39
Net Receivables 81
Inventory 157
Total Current Assets  (as reported)304
Total Current Assets  (calculated)277
+/- 27
Long-term Assets
Property Plant Equipment 1,265
Long-term Assets  (as reported)0
Long-term Assets  (calculated)1,265
+/- 1,265

Liabilities & Shareholders' Equity

Total Current Liabilities6,990
Long-term Liabilities425
Total Stockholder Equity-7,110
Total Current Liabilities
Short Long Term Debt 6,029
Accounts payable 790
Total Current Liabilities  (as reported)6,990
Total Current Liabilities  (calculated)6,819
+/- 170
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt553
Long-term Liabilities  (as reported)425
Long-term Liabilities  (calculated)553
+/- 128
Total Stockholder Equity
Total Stockholder Equity (as reported)-7,110
Total Stockholder Equity (calculated)0
+/- 7,110
Other
Capital Stock23,991
Common Stock Shares Outstanding 132,634
Net Debt 5,990
Net Invested Capital -1,082
Net Working Capital -6,686



6.2. Balance Sheets Structured

Currency in CAD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
337
0
0
215
3,666
2,441
1,520
1,849
2,430
2,574
1,890
2,989
2,010
5,541
4,547
3,352
2,672
2,252
1,863
2,784
1,997
1,959
3,143
2,623
1,673
1,478
1,340
3,702
3,135
4,481
4,835
4,609
4,348
3,546
2,588
2,673
1,691
963
885
1,172
1,086
1,092
1,009
858
800
304
3048008581,0091,0921,0861,1728859631,6912,6732,5883,5464,3484,6094,8354,4813,1353,7021,3401,4781,6732,6233,1431,9591,9972,7841,8632,2522,6723,3524,5475,5412,0102,9891,8902,5742,4301,8491,5202,4413,666215003370
   > Total Current Assets 
0
331
312
0
153
3,661
2,436
1,513
615
1,385
1,158
581
1,757
804
4,398
3,476
2,340
1,715
1,350
1,011
1,975
1,235
686
1,947
1,504
1,108
987
923
3,303
2,768
4,112
4,491
3,779
3,593
2,826
1,880
1,282
903
209
166
487
436
475
425
307
282
304
3042823074254754364871662099031,2821,8802,8263,5933,7794,4914,1122,7683,3039239871,1081,5041,9476861,2351,9751,0111,3501,7152,3403,4764,3988041,7575811,1581,3856151,5132,4363,66115303123310
       Cash And Cash Equivalents 
0
312
-312
0
127
3,576
2,270
1,340
385
1,164
768
328
1,192
473
4,059
3,091
1,860
1,165
842
451
983
370
405
1,457
1,049
485
329
325
2,338
1,719
3,337
3,628
2,886
2,392
2,238
1,386
764
250
44
30
112
170
242
44
25
50
39
3950254424217011230442507641,3862,2382,3922,8863,6283,3371,7192,3383253294851,0491,4574053709834518421,1651,8603,0914,0594731,1923287681,1643851,3402,2703,5761270-3123120
       Short-term Investments 
0
0
623
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45
45
45
45
45
45
45
45
45
45
45
45
45
0
0
0
0
00004545454545454545454545454500000000000000000000000000062300
       Net Receivables 
0
9
0
0
19
75
119
61
96
94
200
121
392
190
221
212
329
430
399
422
851
731
204
433
396
556
598
551
630
780
485
635
672
941
266
297
275
310
2
11
70
32
36
110
56
49
81
81495611036327011231027529726694167263548578063055159855639643320473185142239943032921222119039212120094966111975190090
       Other Current Assets 
0
19
0
0
25
85
166
173
229
221
190
132
173
140
118
173
151
139
109
139
141
121
67
52
54
62
60
47
335
147
180
130
74
120
192
42
113
204
49
48
76
65
74
0
0
0
0
000074657648492041134219212074130180147335476062545267121141139109139151173118140173132190221229173166852500190
   > Long-term Assets 
0
7
-312
0
63
5
5
7
1,235
1,045
1,416
1,308
1,232
1,207
1,142
1,071
1,012
957
902
852
809
761
1,273
1,196
1,118
565
491
417
399
366
369
344
830
755
720
708
1,390
789
754
719
685
651
618
584
551
518
0
05185515846186516857197547891,3907087207558303443693663994174915651,1181,1961,2737618098529029571,0121,0711,1421,2071,2321,3081,4161,0451,235755630-31270
       Property Plant Equipment 
0
7
0
0
6
5
5
7
7
7
6
5
4
46
48
44
39
35
31
32
33
28
571
547
512
480
449
417
399
366
334
304
274
242
211
179
824
789
754
719
685
651
618
584
551
518
1,265
1,2655185515846186516857197547898241792112422743043343663994174494805125475712833323135394448464567775560070
       Intangible Assets 
0
0
0
0
0
0
0
0
814
763
1,200
1,157
1,115
1,073
1,030
988
945
903
861
818
776
733
701
649
606
85
42
0
0
0
35
40
45
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000045403500042856066497017337768188619039459881,0301,0731,1151,1571,20076381400000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
88
64
40
28
19
10
2
0
0
0
0
0
0
0
0
0
0
0
0
512
513
509
529
567
0
0
0
0
0
0
0
0
0
0
000000000056752950951351200000000000021019284064880000000000000
> Total Liabilities 
0
57
0
0
322
745
373
468
944
1,145
571
1,084
706
744
657
848
556
367
397
570
540
315
935
2,328
2,437
2,550
2,717
2,751
3,069
2,561
2,451
2,408
2,519
2,559
2,654
2,452
3,037
3,072
3,082
3,679
4,759
5,380
6,040
6,623
7,078
7,255
7,415
7,4157,2557,0786,6236,0405,3804,7593,6793,0823,0723,0372,4522,6542,5592,5192,4082,4512,5613,0692,7512,7172,5502,4372,3289353155405703973675568486577447061,0845711,14594446837374532200570
   > Total Current Liabilities 
0
57
0
0
322
745
373
468
944
1,145
571
1,084
706
744
657
848
556
367
397
570
540
315
509
445
544
476
576
491
789
384
509
441
2,386
2,457
2,585
2,416
2,359
2,378
2,415
3,039
4,146
4,796
5,487
6,100
6,587
6,796
6,990
6,9906,7966,5876,1005,4874,7964,1463,0392,4152,3782,3592,4162,5852,4572,3864415093847894915764765444455093155405703973675568486577447061,0845711,14594446837374532200570
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96
142
143
144
144
145
146
147
148
149
2,019
2,078
2,138
2,153
2,154
89
2,194
2,700
3,475
4,480
5,119
0
0
0
0
00005,1194,4803,4752,7002,194892,1542,1532,1382,0782,019149148147146145144144143142960000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96
0
0
0
0
0
0
0
0
0
1,869
1,927
1,986
2,000
2,000
2,000
0
0
3,370
4,370
5,005
5,555
5,927
6,029
6,029
6,0296,0295,9275,5555,0054,3703,370002,0002,0002,0001,9861,9271,869000000000960000000000000000000000
       Accounts payable 
0
57
0
0
263
617
304
376
814
1,020
477
884
620
705
621
747
397
336
367
570
540
269
338
245
251
250
335
313
508
161
235
230
180
157
278
96
117
88
139
239
496
274
339
348
451
543
790
79054345134833927449623913988117962781571802302351615083133352502512453382695405703673363977476217056208844771,02081437630461726300570
       Other Current Liabilities 
0
0
0
0
59
128
69
92
131
125
94
200
86
39
37
101
159
31
30
0
0
46
75
58
150
83
96
33
134
76
126
62
187
222
168
167
88
2,200
82
101
176
42
29
0
0
0
0
00002942176101822,200881671682221876212676134339683150587546003031159101373986200941251319269128590000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
427
1,883
1,893
2,074
2,141
2,260
2,281
2,176
1,941
1,967
133
102
69
36
678
694
667
640
612
584
553
523
491
459
425
42545949152355358461264066769467836691021331,9671,9412,1762,2812,2602,1412,0741,8931,8834270000000000000000000000
> Total Stockholder Equity
0
281
281
0
-107
2,921
2,068
1,052
905
1,285
2,003
806
2,283
1,266
4,883
3,699
2,796
2,305
1,855
1,293
2,244
1,682
1,024
815
186
-877
-1,239
-1,411
632
574
2,030
2,427
2,089
1,789
892
136
-364
-1,380
-2,120
-2,794
-3,587
-4,294
-4,948
-5,614
-6,220
-6,455
-7,110
-7,110-6,455-6,220-5,614-4,948-4,294-3,587-2,794-2,120-1,380-3641368921,7892,0892,4272,030574632-1,411-1,239-8771868151,0241,6822,2441,2931,8552,3052,7963,6994,8831,2662,2838062,0031,2859051,0522,0682,921-10702812810
   Common Stock
0
1,195
0
0
1,711
2,029
5,629
5,694
6,712
7,582
10,097
10,097
12,556
12,607
17,168
17,088
17,095
17,095
17,399
17,443
18,943
18,935
18,935
19,131
19,118
19,083
19,083
19,065
21,173
21,172
23,166
23,991
23,991
23,991
23,991
23,991
23,991
23,991
23,991
23,991
23,991
23,991
23,991
0
0
0
0
000023,99123,99123,99123,99123,99123,99123,99123,99123,99123,99123,99123,99123,16621,17221,17319,06519,08319,08319,11819,13118,93518,93518,94317,44317,39917,09517,09517,08817,16812,60712,55610,09710,0977,5826,7125,6945,6292,0291,711001,1950
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
281
0
61
3,600
0
0
0
720
0
0
0
0
0
0
0
0
0
3,080
3,182
0
0
0
0
0
0
0
0
4,102
4,186
4,236
4,280
4,308
4,327
4,343
4,344
4,349
4,353
4,380
4,391
4,400
4,407
0
0
0
0
00004,4074,4004,3914,3804,3534,3494,3444,3434,3274,3084,2804,2364,1864,102000000003,1823,0800000000007200003,60061028100
   Capital Surplus 00000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
715
0
0
812
1,333
1,606
1,668
1,866
2,035
2,122
2,314
2,422
2,523
2,593
2,766
2,807
2,956
3,019
17,443
18,943
3,297
3,368
3,641
3,685
3,695
3,738
3,806
3,994
4,102
4,186
4,236
4,280
4,308
4,327
4,343
4,344
0
0
4,380
0
0
0
0
0
0
0
00000004,380004,3444,3434,3274,3084,2804,2364,1864,1023,9943,8063,7383,6953,6853,6413,3683,29718,94317,4433,0192,9562,8072,7662,5932,5232,4222,3142,1222,0351,8661,6681,6061,333812007150



6.3. Balance Sheets

Currency in CAD. All numbers in thousands.




6.4. Cash Flows

Currency in CAD. All numbers in thousands.




6.5. Income Statements

Currency in CAD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in CAD. All numbers in thousands.

Gross Profit (+$)
totalRevenue584
Cost of Revenue-252
Gross Profit332332
 
Operating Income (+$)
Gross Profit332
Operating Expense-2,711
Operating Income-2,127-2,379
 
Operating Expense (+$)
Research Development0
Selling General Administrative2,327
Selling And Marketing Expenses0
Operating Expense2,7112,327
 
Net Interest Income (+$)
Interest Income5
Interest Expense-253
Other Finance Cost-0
Net Interest Income-248
 
Pretax Income (+$)
Operating Income-2,127
Net Interest Income-248
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,178-2,325
EBIT - interestExpense = -253
-2,178
-1,924
Interest Expense253
Earnings Before Interest and Taxes (EBIT)0-1,924
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-2,178
Tax Provision-0
Net Income From Continuing Ops-2,178-2,178
Net Income-2,178
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net198248
 

Technical Analysis of Aequus Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aequus Pharmaceuticals Inc. The general trend of Aequus Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aequus Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aequus Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aequus Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.005 < 0.005 < 0.005.

The bearish price targets are: 0.005 > 0.005 > 0.005.

Know someone who trades $AQS? Share this with them.πŸ‘‡

Aequus Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aequus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aequus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aequus Pharmaceuticals Inc. The current macd is -0.000012.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aequus Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aequus Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aequus Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aequus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAequus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aequus Pharmaceuticals Inc. The current adx is 18.75.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aequus Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Aequus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aequus Pharmaceuticals Inc. The current sar is 0.00661298.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aequus Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aequus Pharmaceuticals Inc. The current rsi is 46.71. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Aequus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAequus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aequus Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aequus Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aequus Pharmaceuticals Inc Daily Stochastic Oscillator ChartAequus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aequus Pharmaceuticals Inc. The current cci is -66.66666667.

Aequus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAequus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aequus Pharmaceuticals Inc. The current cmo is -9.05057681.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aequus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAequus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aequus Pharmaceuticals Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aequus Pharmaceuticals Inc Daily Williams %R ChartAequus Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aequus Pharmaceuticals Inc. The current atr is 0.000026.

Aequus Pharmaceuticals Inc Daily Average True Range (ATR) ChartAequus Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aequus Pharmaceuticals Inc. The current obv is 1,945,524.

Aequus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAequus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aequus Pharmaceuticals Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aequus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAequus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aequus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Aequus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aequus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.711
Ma 20Greater thanMa 500.005
Ma 50Greater thanMa 1000.005
Ma 100Greater thanMa 2000.006
OpenGreater thanClose0.005
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aequus Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Aequus Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aequus Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aequus Pharmaceuticals Inc

I send you an email if I find something interesting about Aequus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aequus Pharmaceuticals Inc.

Receive notifications about Aequus Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.